Please assess the completion status of the following clinical trial:

Trial Title: Beneficial Bacteria Treatment for Autism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children ages 7-17 years~2. Diagnosis of autism per Autism Diagnostic Interview-Revised (ADI-R)~3. Moderate or Severe GI problems ( on the GSRS, a single score of 4 (severe) on any item, or a score of 3 (moderate) on two items, or a score of 2 (mild) or more on any 4 items~4. No changes in medications, supplements, diet, therapies, or education in last 3 months, and no intention to change them during clinical trial~5. General good physical health aside from gastrointestinal problems~6. Cognitive Ability to Provide Informed Assent~Exclusion Criteria:~1. Antibiotics in last 6 months~2. Probiotics in last 3 months~3. Single-gene disorder (Fragile X, etc.)~4. Major brain malformation~5. Tube feeding~6. Severe gastrointestinal problems that require immediate treatment (life-threatening)~7. Ulcerative Colitis, Crohn's Disease, diagnosed Celiac Disease, Eosinophilic Gastroenteritis, or similar conditions~8. Severely underweight/malnourished~9. Recent or scheduled surgeries~10. Current participation in other clinical trials

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Oral Group (Type: EXPERIMENTAL): This group will receive all treatments orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
- Rectal Group (Type: EXPERIMENTAL): This group will receive some treatments rectally and some orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.

Based on this trial design, predict the completion outcome and termination type (if applicable).